Preclinical evaluation and first-in-human study of [¹⁸F]AlF-FAP-NUR for PET imaging cancer-associated fibroblasts.

ABSTRACT:

Background

Fibroblast activation protein (FAP) has gained attention as a promising molecular target with potential utility for cancer diagnosis and therapy. [⁶⁸Ga]Ga-labeled FAP-targeting peptides have been successfully applied to positron emission tomography (PET) imaging of various tumor types. To meet the applicable demand for peptide-based FAP tracers with high patient throughput, we herein report the radiosynthesis, preclinical evaluation, and the first-in-human imaging of a novel [¹⁸F]F-labeled FAP-targeting peptide.

Results

[¹⁸F]AlF-FAP-NUR was automatedly prepared within 45 min with a non-decay corrected radiochemical yield of 18.73 ± 4.25% (n = 3). Compared to [⁶⁸Ga]Ga-FAP-2286, the [¹⁸F]F-labeled peptide demons

SUBMITTER: Liu S 

PROVIDER: S-EPMC11445204 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature